In this webinar, experts take a deep dive into Delphi panel methods, their implementation, and pharmaceutical industry insights on the panels' uses and outcomes.
For over 15 years, PHAR has conducted RAND/UCLA modified Delphi panels, a systematic and validated way to obtain consensus among clinicians and other experts, such as patient advocates. The speakers broadly present different methods for gaining consensus, including the different Delphi panel approaches that exist, the history of the method's use, the behavioral science behind why these panels work, how these panels are conducted (both in person and virtually), and the outcomes of the panels.
Alongside PHAR President Dr. Michael Broder, two senior researchers from the pharmaceutical industry provide their perspective on leading these panels (including why sometimes it's recommended they are blinded to all aspects), their experience participating in the discussions, and how they have used the results.
*Partnership for Health Analytic Research (PHAR) has been acquired by ADVI Health. This marks a new chapter for PHAR, as they join ADVI's Strategic Analytics, Value, and Economics (SAVEs) team. Together, they will continue delivering high-impact, data-informed insights while enhancing our service offerings in the life sciences sector. For more details, please visit ADVI Health's official announcement.*
Key Topics Include:
- Overview of the different ways to obtain consensus from expert clinicians
- The broad steps involved in conducting a RAND/UCLA modified Delphi panel method
- The possible outcomes of such a panel
- Benefits and challenges of this method
Presenters
Kathleen Villa
Kathleen Villa is the Executive Director of Medical Evidence Generation at Ionis Pharmaceuticals. In this role, she collaborates with cross-functional teams to evaluate unmet medical needs and generates data to help health care professionals make well-informed treatment decisions. Kathleen has over 20 years of experience as a pharma industry health economist and health outcomes researcher. Most of her roles have been in Medical Affairs, with additional experience in strategic planning, consulting, and digital health.
Kathleen was previously at Gilead Sciences where she developed and implemented the cross-functional Integrated Evidence Planning process across all therapeutic areas. She also led the Health Outcomes Research team at Evidation Health, spent several years as a health economist at Genentech supporting the Cardiovascular and Neuroscience TAs, and was the global head of Health Economics and Outcomes Research (HEOR) at Jazz Pharmaceuticals. Kathleen has expertise in observational research, health economic studies and modeling, survey research, patient-reported outcomes, and strategic evidence generation planning, and earned her MS in Evaluative Clinical Sciences at Dartmouth College.
Michael Broder
Dr. Michael Broder has 30 years' experience in health economic and outcomes research. He has conducted dozens of expert panels on a wide variety of topics. In addition to being an experienced health services researcher, he is a board-certified physician and provides clinical expertise for many studies at PHAR.
Tiffany Quock
Tiffany P. Quock, PhD, MS is an epidemiologist and health economist by training, with nearly 20 years of experience in HEOR, RWE, and Global Value and Access. She is currently the Vice President, Health Economics and Outcomes Research at Crinetics Pharmaceuticals, a San Diego based pharmaceuticals company developing therapies for people with endocrine diseases and endocrine-related disorders. Previously, Dr. Quock was the Head of Global Health Economics and Outcomes Research, and Head of Medical Affairs at Prothena Biosciences, where she had worked in Zug, Switzerland to support the European launch. She has experience across a multitude of therapeutic areas, including rare diseases, neuroscience, oncology/hematology, and inflammatory conditions. Dr. Quock started her career as a Visiting Assistant Professor and Researcher at UCLA, David Geffen School of Medicine, where she taught research methods to graduate students and RWJF Health Policy Fellows. During her time at UCLA, she conducted research on breast cancer and neurodegenerative diseases. She has also worked at Amgen, ICON plc, and Jazz Pharmaceuticals with increasing responsibilities, leading teams as well as designing evidence throughout the entire product lifecycle to support approval and market access.
Dr. Quock has expertise identifying appropriate PRO endpoints for clinical trials, developing and validating de novo PRO instruments in rare diseases, designing RWE studies and economic models to frame value propositions, and developing compelling evidence for negotiations with HTA agencies. She received her PhD and MS in Health Services Research, with Cognates in Health Care Outcomes Research and Epidemiology at UCLA. In addition, Dr. Quock completed fellowships in Cancer Control at UCSF, Economics and Epidemiology at Pardee RAND Graduate School, and Entrepreneurship at Stanford University Graduate School of Business.
Sponsor
